{
    "clinical_study": {
        "@rank": "162999", 
        "arm_group": [
            {
                "arm_group_label": "BI 207127 bid low dose", 
                "arm_group_type": "Experimental", 
                "description": "tablets, oral administration with 240 mL water under fed conditions"
            }, 
            {
                "arm_group_label": "BI 207127 bid high dose", 
                "arm_group_type": "Experimental", 
                "description": "tablets, oral administration with 240 mL water under fed conditions"
            }, 
            {
                "arm_group_label": "BI 207127 bid high dose+faldaprevir qd", 
                "arm_group_type": "Experimental", 
                "description": "tablets/capsules, oral administration with 240 mL water under fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the current trial is to evaluate safety, tolerability and pharmacokinetics\n      of different multiple doses of BI 207127 BID and multiple doses of BI 207127 combined with\n      faldaprevir in healthy male and female subjects."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. healthy male and female subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737996", 
            "org_study_id": "1241.35", 
            "secondary_id": "2012-003697-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 207127 bid high dose", 
                "description": "tablets, oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 bid high dose+faldaprevir qd", 
                "description": "fixed dose combination", 
                "intervention_name": "BI 207127 + faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 bid low dose", 
                "description": "tablets, oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany"
                }, 
                "name": "1241.35.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Multiple Dose Study to Assess Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID Administered Orally for 9 Days (Part 1) and Multiple Doses of BI 207127 Combined With Faldaprevir Administered Orally for 16 Days (Part 2) in Healthy Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCt (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "Ct (concentration of the analyte in plasma at steady state at the end of the dosing interval t) (only for BI 207127 and metabolites)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "Ct,ss (concentration of the analyte in plasma at steady state at the end of the dosing interval t) (only for BI 207127 and metabolites)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "C12 (measured concentration of the analyte in plasma at 12 hours)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUC0-infinity area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "%AUCtz-infinity (the percentage of AUC0-infinity obtained by extrapolation)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "t1/2 (terminal half-life of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "C12,ss (measured concentration of the analyte in plasma at steady state at 12 hours)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "t1/2,ss (terminal half-life of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "RA,Cmax (accumulation ratio based on Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "RA,AUC (accumulation ratio based on AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}